- CEO
- Xiao Dong Gao
- Full Time Employees
- 1,194
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No. 71 Menglong Street, South Zone Shijiazhuang HE China 050800
- IPO Date
- Aug 5, 2011
- Business
- Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biochemical pharmaceutical products with a focus on heparin series products. The company’s core product portfolio includes heparin sodium active pharmaceutical ingredients (APIs); crude heparin; low molecular weight heparins (LMWH) such as enoxaparin sodium, nadroparin calcium, and dalteparin sodium; heparin calcium injections; heparin sodium injections; heparin lithium injectables; sodium hyaluronate in both cosmetic and food-grade forms; hard capsules; anti-aging dietary supplements branded as Yihaitang capsules; and additional finished dosage forms like small-volume injections. These products primarily target the prevention and treatment of cardiovascular and cerebrovascular diseases, including cerebral vascular conditions, arteriosclerosis, myocardial infarction, and phlebitis. The company also is involved in the expansion of its portfolio into multidisciplinary innovative drugs, including diabetes treatment and antineoplastic drugs. Hebei Changshan operates under GMP standards and distributes its products domestically in China and internationally across countries including the United States, Germany, France, Italy, Spain, South Korea, Japan, Russia, India, and the Philippines. Founded in 2000 and headquartered in Hebei, China, the company has established a strong technical team and a complete heparin industrial chain supporting its product lines.
Recent significant developments include the clinical trial approval of Aibennatide, a GLP-1 receptor agonist injection for weight loss indications, complementing its prior approval application for type 2 diabetes treatment. The company’s controlling shareholder planned a strategic divestment by selling a 5% stake valued at approximately 2.1 billion yuan in 2025. Hebei Changshan has also been advancing its R&D focus on innovative therapies such as NTRK inhibitors and c-Met targeted antineoplastic agents, reflecting a shift toward pharmaceutical innovation and precision medicine. The company’s strategic expansions incorporate commercial insurance breakthroughs for innovative drugs and growth in overseas authorization trades, aligning with industry trends and regulatory changes in China’s pharmaceutical sector. These moves indicate Hebei Changshan's commitment to evolving beyond its established heparin products into broader biopharmaceutical research and international market penetration.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. remains a key player in the biochemical pharmaceutical industry with strong positions in heparin APIs and preparations, operating globally with a strategic emphasis on cardiovascular, cerebrovascular, diabetes, and oncology therapeutic areas. Its comprehensive product range, robust technical capabilities, ongoing innovative drug development, and recent strategic investments underscore its growth trajectory within China and international markets.